Effective price: ₹2524
All age group
ROMA (Risk of Ovarian Malignancy Algorithm) test assesses whether a woman with ovarian adnexal mass has a low or high chance of finding malignancy during surgery.
Ovarian cancer is relatively uncommon but causes more deaths than any form of cancer. The rapid growth and multiplication of cells in the ovary causes ovarian cancer. These cells are responsible for invading and destroying healthy body tissues.
A doctor may not immediately diagnose this condition since it does not pose any noticeable symptoms initially. Thus, it is vital to take the ROMA test to detect the condition early.
ROMA is a qualitative serum test that is primarily used for detecting epithelial cell ovarian cancer in premenopausal and postmenopausal women.
This test combines the result of the monitoring tests, namely HE4 and CA125, and menopausal status. It releases this result in the form of a numerical score.
If the patient is premenopausal and receives a score less than 1.14, then it is highly likely that there will be no malignancy found during surgery. On the other hand, for postmenopausal women, any score less than 2.99 indicates a low chance of malignancy.
To be eligible for the ROMA test, a woman must fulfil all of the following criteria.
ROMA test must be undertaken and interpreted in conjunction with clinical and radiological tests. The entire procedure does not require any special preparations. But it is advisable to stop consuming any supplement with a high dose of biotin before the test. The biotin intake should be stopped at least 72 hours before the test is taken. Otherwise, there might be interference with the results, and you may not receive an accurate conclusion.
The earlier ovarian cancer is detected, the easier it is to treat successfully. The condition poses no noticeable symptoms in its initial stages, and a lot of its symptoms overlap with common ailments. Some of them include:
The ROMA test helps determine the likelihood of having ovarian cancer by distinguishing epithelial ovarian cancer from benign pelvic mass.
Why should Apollo be your preferred healthcare partner?
The information mentioned above is meant for educational purposes only and should not be taken as a substitute to your Physician’s advice. It is highly recommended that the customer consults with a qualified healthcare professional to interpret test results